FLUIDIGM CORP (FLDM)

Common Stock

3.71  -0.28 (-7.02%)

After market: 4.02 +0.31 (+8.36%)

Fundamental Rating

1

Taking everything into account, FLDM scores 1 out of 10 in our fundamental rating. FLDM was compared to 59 industry peers in the Life Sciences Tools & Services industry. FLDM has a bad profitability rating. Also its financial health evaluation is rather negative. FLDM does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FLDM has reported negative net income.
FLDM had negative earnings in each of the past 5 years.
FLDM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Industry RankSector Rank
ROA -21.52%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -51.66%
PM (TTM) -45.36%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

FLDM has more shares outstanding than it did 1 year ago.
FLDM has a worse debt/assets ratio than last year.

2.2 Solvency

FLDM has an Altman-Z score of -2.94. This is a bad value and indicates that FLDM is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.68 indicates that FLDM is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z -2.94
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

FLDM has a Current Ratio of 1.45. This is a normal value and indicates that FLDM is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.03 indicates that FLDM should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 1.03

More info and screens

2

3. Growth

3.1 Past

FLDM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.85%.
The Revenue has decreased by -5.48% in the past year.
FLDM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.58% yearly.
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q50%
Revenue 1Y (TTM)-5.48%
Revenue growth 3Y4.94%
Revenue growth 5Y4.58%
Revenue growth Q2Q-14.22%

3.2 Future

The Earnings Per Share is expected to decrease by -4.60% on average over the next years.
Based on estimates for the next years, FLDM will show a small growth in Revenue. The Revenue will grow by 4.08% on average per year.
EPS Next Y-30.77%
EPS Next 2Y-17.18%
EPS Next 3Y-8.28%
EPS Next 5Y-4.6%
Revenue Next Year-0.48%
Revenue Next 2Y4.54%
Revenue Next 3Y3.89%
Revenue Next 5Y4.08%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FLDM. In the last year negative earnings were reported.
Also next year FLDM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -6.32

4.3 Compensation for Growth

FLDM's earnings are expected to decrease with -8.28% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.18%
EPS Next 3Y-8.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FLDM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FLUIDIGM CORP

NASDAQ:FLDM (4/5/2022, 7:24:22 PM)

After market: 4.02 +0.31 (+8.36%)

3.71

-0.28 (-7.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap285.37M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.52%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -51.66%
PM (TTM) -45.36%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.45
Quick Ratio 1.03
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-30.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-5.48%
Revenue growth 3Y4.94%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y